Therapeutic Activity and Biodistribution of a Nano-Sized Polymer-Dexamethasone Conjugate Intended for the Targeted Treatment of Rheumatoid Arthritis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22310%2F23%3A43927233" target="_blank" >RIV/60461373:22310/23:43927233 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Therapeutic Activity and Biodistribution of a Nano-Sized Polymer-Dexamethasone Conjugate Intended for the Targeted Treatment of Rheumatoid Arthritis

Popis výsledku v původním jazyce

Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the biodistribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2 hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo imaging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of a stimuli-sensitive spacer is a suitable strategy for improving rheumatoid arthritis therapy.

Název v anglickém jazyce

Therapeutic Activity and Biodistribution of a Nano-Sized Polymer-Dexamethasone Conjugate Intended for the Targeted Treatment of Rheumatoid Arthritis

Popis výsledku anglicky

Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the biodistribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2 hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo imaging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of a stimuli-sensitive spacer is a suitable strategy for improving rheumatoid arthritis therapy.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

10404 - Polymer science

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nanomedicine-Nanotechnology Biology and Medicine

ISSN

1549-9634

e-ISSN

1549-9642

Svazek periodika

¨Neuveden

Číslo periodika v rámci svazku

April

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

21

Strana od-do

"Nestrankovano"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—